Regula Wins High Customer Marks and Strong Momentum in G2’s Winter 2026 Grid Reports for Identity Verification
18.12.2025 14:11:00 CET | Business Wire | Press release
Regula, a global developer of identity verification solutions, has been recognized by customers on G2’s review platform as one of the fastest-rising and most trusted vendors in the identity verification market. Regula is named as a Leader in three G2 Winter 2026 Grid® Reports for Identity Verification.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218134153/en/

Regula is recognized as a Leader in G2’s Winter 2026 Grid Reports for Identity Verification, reflecting strong customer satisfaction and enterprise-grade IDV capabilities.
This season, Regula earned a Leader placement in G2’s Overall Grid® for Identity Verification Software, reflecting strong customer satisfaction and a growing presence in the market. The company was also named a Leader in the Momentum Grid® Report for Identity Verification, highlighting accelerating demand for Regula’s solutions and increasingly positive feedback from users. In addition, Regula appeared as a Leader in the EMEA Regional Grid® Report for Identity Verification, underscoring rapid growth across Europe, the Middle East, and Africa — regions where high-assurance, forensic-grade verification is especially critical.
Rather than being about badges alone, these recognitions signal a broader trend: organizations are shifting toward deeper, science-driven identity verification in response to rising fraud and document complexity — and Regula is becoming a preferred partner for solving those challenges.
A year of strong, measurable growth
These recognitions come on the heels of another milestone year for Regula, which included:
- Launching its all-in-one IDV platform.
- Expanding the world’s largest library of identity document templates to 16,000.
- Standing out as the only vendor in NIST’s Face Recognition Vendor Test (FRVT) to earn top-tier results across all critical age-estimation tests.
- Growing customer adoption across banking, fintech, aviation, telecom, and government.
Together, these advancements reflect Regula’s focus on delivering border-grade precision in identity verification at enterprise scale, at a time when identity fraud is evolving faster than ever.
“Customer trust is the clearest signal of product-market fit,” said Ihar Kliashchou, Chief Technology Officer at Regula. “Seeing Regula recognized as both a Leader and a fast mover on G2 shows that our approach resonates: organizations want verification that is accurate, forensic-grade, and built to stay ahead of AI-driven fraud. We’re grateful to our customers for their confidence — it motivates us to keep raising the bar.”
Why this matters for the market
Identity verification is moving from being a compliance checkpoint to becoming a strategic pillar of security. With AI-generated fraud surging and document forgery becoming easier to automate, businesses increasingly look for partners who can combine:
- Deep document forensics.
- Advanced biometric checks.
- End-to-end verification orchestration.
- Deployment flexibility across cloud, on-prem, and hybrid.
G2’s Winter 2026 acknowledgements confirm that Regula is not only competing in this landscape but setting a higher standard for what reliable verification should look like.
About G2
G2 is the world’s largest and most trusted software marketplace. More than 100 million people annually — including employees at all Fortune 500 companies — use G2 to make smarter software decisions based on authentic peer reviews. Thousands of software and services companies of all sizes partner with G2 to build their reputation and grow their business — including Salesforce, HubSpot, Zoom, and Adobe. To learn more about where you go for software, visit www.g2.com.
About Regula
Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the most comprehensive library of document templates in the world, we create breakthrough technologies for document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed. Regula has been recognized in the 2025 Gartner® Magic Quadrant™ for Identity Verification.
Learn more at www.regulaforensics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251218134153/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom